In Austria, the first vaccine against the Chikungunya -Tropical disease is now offered. This allows travelers to protect themselves against an infection in countries in which the virus is endemic. These include states in North and South America, Africa and Asia.
The chikungunya virus is transmitted by mosquitoes and can cause general discomfort with fever and severe muscle and joint pain. The joint pain can even take years. Other possible symptoms are headache, nausea, fatigue and rash.
According to the ECDC of the European Health Authority, 620,000 cases were registered worldwide in the previous year. However, experts assume that the actual number is higher due to difficulties in diagnosis and reporting. Chikungunya is diagnosed by blood tests in the first week of symptoms. Antibodies can then be proven for up to two months after the infection.
The first vaccine against tropical disease has now been developed by the Austrian-French pharmaceutical company Valneva in Vienna. IXCHIQ can be ordered in all pharmacies and are administered as a single dose of adults from the age of 18. Vacancy is also approved in the US, Canada, Great Britain and the EU. “Valneva also works with partners on programs to make the vaccine available in countries with a low and medium -size income,” says a broadcast.
Source: Krone
I am Wallace Jones, an experienced journalist. I specialize in writing for the world section of Today Times Live. With over a decade of experience, I have developed an eye for detail when it comes to reporting on local and global stories. My passion lies in uncovering the truth through my investigative skills and creating thought-provoking content that resonates with readers worldwide.
